Amneal faces hydroxychloroquine API shortage after Finland tightens production: report

13th April 2020 Uncategorised 0

In a rush to contribute an antimalarial med to the COVID-19 fight, drugmakers have promised millions of doses for clinical trials and hospitals. But one company, Amneal Pharmaceuticals, likely won’t hit its pledge after the government of Finland effectively turned off the tap for necessary ingredients.

More: Amneal faces hydroxychloroquine API shortage after Finland tightens production: report
Source: fierce